Sugiyama Masahiro, Sakahara Harumi, Sato Kengo, Harada Norihiro, Fukumoto Dai, Kakiuchi Takeharu, Hirano Toru, Kohno Eiji, Tsukada Hideo
Department of Radiology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
J Nucl Med. 2004 Oct;45(10):1754-8.
3'-Deoxy-3'-18F-fluorothymidine (18F-FLT) has been suggested as a new PET tracer for imaging tumor proliferation. We investigated the use of 18F-FLT to monitor the response of tumors to radiotherapy and photodynamic therapy (PDT) in mice.
C3H/He mice bearing an SCCVII tumor were treated with single-dose x-ray irradiation of 20 Gy. Tumor uptake was examined for 18F-FLT, 3H-thymidine (3H-Thd), 18F-FDG, and 14C-deoxyglucose (14C-DG) at 6 h, 12 h, 24 h, 3 d, and 7 d after radiotherapy. BALB/c nu/nu mice bearing a HeLa tumor were treated with PDT. Tumor uptake was examined for the 4 tracers at 24 h after PDT. Expression of proliferating cell nuclear antigen (PCNA) was determined in untreated and treated tumors.
In the biodistribution study, considerable uptake of 18F-FLT was observed in both tumor types. Tumor volumes decreased to 39.3% +/- 22.4% at 7 d after radiotherapy. The PCNA labeling index was reduced in x-ray-irradiated tumors (control, 53.2% +/- 8.7%; 6 h, 38.5% +/- 5.3%; 24 h after radiotherapy, 36.8% +/- 5.3%). 18F-FLT uptake in tumor expressed as the percentage of the injected dose per gram of tumor (%ID/g) decreased significantly at 6 h and remained low until 3 d after radiotherapy (control, 9.7 +/- 1.2 %ID/g; 6 h, 5.9 +/- 0.4 %ID/g; 24 h, 6.1 +/- 1.3 %ID/g; 3 d after radiotherapy, 6.4 +/- 1.1 %ID/g). 18F-FDG uptake tended to gradually decrease but a significant decrease was found only at 3 d (control, 12.1 +/- 2.7 %ID/g; 6 h, 13.3 +/- 2.3 %ID/g; 24 h, 8.6 +/- 1.8 %ID/g; 3 d after radiotherapy, 6.9 +/- 1.2 %ID/g). PDT resulted in a reduction of the PCNA labeling index (control, 82.0% +/- 8.6%; 24 h after PDT, 13.5% +/- 12.7%). Tumor uptake of 18F-FLT decreased (control, 11.1 +/- 1.3 %ID/g; 24 h after PDT, 4.0 +/- 2.2 %ID/g), whereas 18F-FDG uptake did not decrease significantly after PDT (control, 3.5 +/- 0.6 %ID/g; 24 h after PDT, 2.3 +/- 1.1 %ID/g). Changes in the uptake of 18F-FLT and 18F-FDG were similar to those of 3H-Thd and 14C-DG, respectively.
In our model system, changes in 18F-FLT uptake after radiotherapy and PDT were correlated with those of 3H-Thd and the PCNA labeling index. The decrease in 18F-FLT uptake after treatments was more rapid or pronounced than that of 18F-FDG. Therefore, 18F-FLT may be a feasible PET tracer for monitoring response to therapy in oncology.
3'-脱氧-3'-¹⁸F-氟胸苷(¹⁸F-FLT)已被提议作为一种用于肿瘤增殖成像的新型正电子发射断层显像(PET)示踪剂。我们研究了¹⁸F-FLT在小鼠中监测肿瘤对放疗和光动力疗法(PDT)反应的应用。
对荷SCCVII肿瘤的C3H/He小鼠进行20 Gy的单剂量X射线照射。在放疗后6小时、12小时、24小时、3天和7天,检测肿瘤对¹⁸F-FLT、³H-胸苷(³H-Thd)、¹⁸F-氟代脱氧葡萄糖(¹⁸F-FDG)和¹⁴C-脱氧葡萄糖(¹⁴C-DG)的摄取。对荷HeLa肿瘤的BALB/c裸鼠进行PDT治疗。在PDT后24小时检测肿瘤对这4种示踪剂的摄取。测定未治疗和治疗后肿瘤中增殖细胞核抗原(PCNA)的表达。
在生物分布研究中,在两种肿瘤类型中均观察到¹⁸F-FLT有相当程度的摄取。放疗后7天肿瘤体积减小至39.3%±22.4%。X射线照射的肿瘤中PCNA标记指数降低(对照组,53.2%±8.7%;6小时,38.5%±5.3%;放疗后24小时,36.8%±5.3%)。肿瘤中¹⁸F-FLT摄取以每克肿瘤注射剂量的百分比(%ID/g)表示,在6小时时显著降低,并在放疗后3天一直保持较低水平(对照组,9.7±1.2 %ID/g;6小时,5.9±0.4 %ID/g;24小时,6.1±1.3 %ID/g;放疗后3天,6.4±1.1 %ID/g)。¹⁸F-FDG摄取倾向于逐渐降低,但仅在3天时发现有显著降低(对照组,12.1±2.7 %ID/g;6小时,13.3±2.3 %ID/g;24小时,8.6±1.8 %ID/g;放疗后3天,6.9±1.2 %ID/g)。PDT导致PCNA标记指数降低(对照组,82.0%±8.6%;PDT后24小时,13.5%±12.7%)。¹⁸F-FLT的肿瘤摄取降低(对照组,11.1±1.3 %ID/g;PDT后24小时,4.0±2.2 %ID/g),而¹⁸F-FDG摄取在PDT后没有显著降低(对照组,3.5±0.6 %ID/g;PDT后24小时,2.3±1.1 %ID/g)。¹⁸F-FLT和¹⁸F-FDG摄取的变化分别与³H-Thd和¹⁴C-DG的变化相似。
在我们的模型系统中,放疗和PDT后¹⁸F-FLT摄取的变化与³H-Thd和PCNA标记指数的变化相关。治疗后¹⁸F-FLT摄取的降低比¹⁸F-FDG更迅速或更明显。因此,¹⁸F-FLT可能是一种用于监测肿瘤学中治疗反应的可行PET示踪剂。